Postoperative radiotherapy in Stage IB squamous cell cervical cancer

Objective: The purpose of the study was to evaluate postoperative whole pelvic radiation for high-risk patients with FIGO Stage IB cervical cancer.

Methods: One hundred and forty-eight patients with Stage IB squamous cell carcinoma of the cervix underwent radical hysterectomy and pelvic lymphadenectomy. The low-risk group included patients without unfavorable prognostic factors who were treated only by surgery. The high-risk group included women with pelvic node metastases, with positive or close surgical margins, clinical tumor size > 4.0 cm, depth of stromal invasion > 1/3 the cervical wall, grade 3 tumor and presence of lymphovascular space involvement. High-risk patients received whole pelvic radiotherapy between two and four weeks after surgery.

Results: Seventy patients (47.3%) were low risk and 78 patients (52.7%) were high risk. Locoregional recurrences were diagnosed in nine cases (12.8%) in the surgery group and in 11 patients (14.1%) assigned to radiotherapy. The incidence of distant metastases was 2.8% in the surgery group and 6.4% in the surgery and radiotherapy group. Overall survival at five years was 88.6% in the low-risk group and 84.7% in the high-risk group.

Conclusion: Five-year overall survival, locoregional and distant metastases were similar in the low-risk and high-risk groups of patients, thus emphasizing the value of whole pelvic radiation in patients with unfavorable prognostic factors in Stage IB cervical cancer.

Stage IB cervical cancer; High-risk patients: Postoperative pelvic radiation

[1] Boring C.C., Squires T.S., Tong T.: "Cancer Statistics". J. Clin. Cancer., 1994, 44, 7.

[2] Creasman W.T.: "New Gynecologic Cancer Staging". Gynecol. Oneal., 1995, 58, 157.

[3] Benedet J.L., Pecorelli S.: "Staging classifications and clinical practice guidelines of gynecologic cancers". J. Gynecol. Obstet., 2000, 70, 207.

[4] Shaw M.C., Wolfe C.D.A., Devaja O., Raju K.S.: "Development of an evidence-based algorithm for the management of cervical cancer". Eur. J. Gynaec. Oneal., 2003, 24, 365.

[5] Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., Major F.: "Prospective surgical-pathological study of disease-free interval in patients with Stage TB squamous cell carcinoma of the cervix: A Gynecology Oncology Group Study". Gynecol. Oneal., 1990, 38, 352.

[6] Sedlis A., Bundy B., Rotman M., Lentz S., Muderspach L., Zaino R.: "A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with Stage 1B carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study". 1999, 7 3, 177.

[7] Lai C.H., Hong J.H., Hsueh S., Ng K.K., Chang T.C., Tseng C. J. et al.: "Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage 1B or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases". Cancer, 1999, 85, 1537.

[8] Ayhan A., Al RA., Baykal C., Demirtas E., Ayhan A., Yuce K.: "Prognostic factors in F IGO stage 1B cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy". Int. J. Gynecol. Cancer, 2004, 14, 286.

[9] Pieterse Q.D., Trimbos J.B.M.Z., Dijkman A., Creutzberg C.L.,Gaarenstroom K.N., Peters A.A.W. et al.: "Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study". Int. J. Gynecol. Cancer, 2006, 16, 1112.

[10] Schorge J.O., Molpus K.L., Koelliker D., Nikrui N., Goodman A., Fuller A.F. Jr.: "Stage 1B and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol. Oncol., 1997, 66, 31.

[11] Kim S.M., Choi H.S., Byun J.S.: "Overall 5-year survival rate and prognostic factors in patients with Stage 1B and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection". Int. J. Gynecol Cancer., 2000, 10, 305.